163
Participants
Start Date
April 27, 2023
Primary Completion Date
March 6, 2025
Study Completion Date
March 6, 2025
Ligelizumab 120 mg
1 injection of 1.0 mL ligelizumab and 1 injection of 1.0 mL placebo
Ligelizumab 240 mg
2 injections of 1.0 mL ligelizumab
Novartis Investigative Site, Parkville
Novartis Investigative Site, Utrecht
Novartis Investigative Site, Brisbane
Novartis Investigative Site, Nedlands
Northwell Health, New York
Novartis Investigative Site, Berlin
UBMD Pediatrics, Buffalo
Childrens Hospital Of Philadelphia, Philadelphia
Johns Hopkins Childrens Center, Baltimore
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Atlanta Allergy and Asthma Clinic, Marietta
Childrens Healthcare of Atlanta, Atlanta
Novartis Investigative Site, Toulouse
Univ of South Florida Asthma Allergy and Immunology CRU, Tampa
Novartis Investigative Site, Padua
Allervie Clinical Research, Birmingham
Family Allergy and Asthma, Louisville
University of Michigan Clinical Trials Office, Ann Arbor
Respiratory Medicine Research Institute of Michigan, Ypsilanti
Novartis Investigative Site, Angers
Novartis Investigative Site, Vandœuvre-lès-Nancy
Novartis Investigative Site, Lille
Novartis Investigative Site, Frankfurt am Main
Novartis Investigative Site, Frankfurt am Main
Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago
Arkansas Children's Hospital, Little Rock
University of Texas Southwestern Medical Center, Dallas
Texas Childrens Hospital, Houston
UCHealth Outpatient Pavilion, Aurora
Asthma and Allergy Associates P C, Colorado Springs
Allergy and Immunology Associates, Scottsdale
Allergy and Asthma Clinical Research Inc, Walnut Creek
Allergy and Asthma Associates of Santa Clara Vally Center, San Jose
Seattle Allergy and Asthma Rsch, Seattle
Boston Childrens Hospital, Boston
Mt Sinai Medical Center, New York
University Of NC At Chapel Hill, Chapel Hill
Cincinnati Childrens Hospital MC, Cincinnati
Novartis Investigative Site, Hamilton
Novartis Investigative Site, Ottawa
Novartis Investigative Site, Toronto
Novartis Investigative Site, Montreal
Novartis Investigative Site, Québec
Novartis Investigative Site, Dresden
Novartis Investigative Site, Sagamihara
Novartis Investigative Site, Setagaya-ku
Novartis Investigative Site, Esplugues de Llobregat
Novartis Investigative Site, Barcelona
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY